These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 1720809

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
    Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME.
    J Clin Invest; 1988 Apr; 81(4):1122-8. PubMed ID: 2450893
    [Abstract] [Full Text] [Related]

  • 23. Structure and function of decay accelerating factor CD55.
    Nicholson-Weller A, Wang CE.
    J Lab Clin Med; 1994 Apr; 123(4):485-91. PubMed ID: 7511675
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C, Walter EI, Medof ME.
    J Immunol; 1990 Dec 01; 145(11):3836-41. PubMed ID: 1700997
    [Abstract] [Full Text] [Related]

  • 26. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions.
    Seifert PS, Hansson GK.
    J Clin Invest; 1989 Aug 01; 84(2):597-604. PubMed ID: 2474572
    [Abstract] [Full Text] [Related]

  • 27. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME, Kinoshita T, Silber R, Nussenzweig V.
    Proc Natl Acad Sci U S A; 1985 May 01; 82(9):2980-4. PubMed ID: 2581259
    [Abstract] [Full Text] [Related]

  • 28. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
    Harris CL, Spiller OB, Morgan BP.
    Immunology; 2000 Aug 01; 100(4):462-70. PubMed ID: 10929073
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T, Inoue T, Ogawa K, Iida K, Tamura N.
    J Exp Med; 1987 Nov 01; 166(5):1221-8. PubMed ID: 2445886
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
    Seya T, Inoue H, Okada M, Matsumoto M, Kitamura H, Kinoshita T, Akedo H.
    Mol Immunol; 1990 Jan 01; 27(1):69-78. PubMed ID: 1690349
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF.
    Tambourgi DV, Kipnis TL, da Silva WD, Joiner KA, Sher A, Heath S, Hall BF, Ogden GB.
    Infect Immun; 1993 Sep 01; 61(9):3656-63. PubMed ID: 7689538
    [Abstract] [Full Text] [Related]

  • 36. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J, Gou D, Zhen C, Jiang D, Mao X, Li W, Chen S, Cai C.
    FEMS Immunol Med Microbiol; 2001 Oct 01; 31(3):203-9. PubMed ID: 11720816
    [Abstract] [Full Text] [Related]

  • 37. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF).
    Nicholson-Weller A, Russian DA, Austen KF.
    J Immunol; 1986 Aug 15; 137(4):1275-9. PubMed ID: 3090145
    [Abstract] [Full Text] [Related]

  • 38. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
    Kim DD, Miwa T, Song WC.
    J Immunol; 2006 Oct 15; 177(8):5558-66. PubMed ID: 17015743
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.
    Zalman LS, Wood LM, Frank MM, Müller-Eberhard HJ.
    J Exp Med; 1987 Feb 01; 165(2):572-7. PubMed ID: 2434597
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.